Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 29, 2012

MRC Technology Lends Expertise to Chinese Academy

  • MRC Technology, a technology transfer charity and company, entered into a strategic drug discovery collaboration with the Shanghai Institute of Biochemistry and Cell Biology (SIBCB), Chinese Academy of Science (CAS). The agreement will combine the SIBCB’s research expertise in generating potential new drug targets, with MRC Technology’s experience in further developing early-stage research for pharmaceutical application and commercialization. The focus of the collaboration is to fast-track innovative drugable targets to create potent and selective novel therapeutics.

    “SIBCB is one of the world’s leading academic research institutions and the initiative reflects our joint commitment to delivering drugs for the treatment of diseases of global significance," Dave Tapolczay, MRC Techology’s CEO commented. "The collaboration gives us a strong partner in China and access to potential new targets to further develop into drug therapies.”

    In May, MRC Technology launched two collaborations with Mauro Perretti, Ph.D., at the William Harvey Research Institute, Queen Mary University of London (QMUL) to exploit G-protein coupled receptors (GPCRs) identified as effectors of endogenous resolution. Also, earlier this month, they received a £577,000 ($916,000) award from the Biomedical Catalyst to fund research into the role of cytokine IL-16 in Ischemic Reperfusion Injury (IRI), the tissue damage and ensuing inflammatory response resulting from a sudden loss of blood flow.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »